Quantcast

Long-Term Comparative Effectiveness of Paclitaxel-Eluting and Everolimus-Eluting Stents in New York ☆

Research paper by Feng Qian, Ye Zhong, Edward L. Hannan

Indexed on: 09 Nov '16Published on: 02 Nov '16Published in: International Journal of Cardiology



Abstract

First generation paclitaxel-eluting stents (PES) and second generation everolimus-eluting stents (EES) were approved for use in percutaneous coronary interventions (PCIs) in 2004 and 2008, respectively. However, relative long-term outcomes of PES vs EES in real practice remain unclear. We sought to determine the long-term comparative effectiveness of PES vs EES using New York State (NYS) cardiac registries and to assess long-term outcomes of PES vs ZES in six “off-label” and two “high-risk” patient subgroups.

Figure 10.1016/j.ijcard.2016.10.116.0.jpg
Figure 10.1016/j.ijcard.2016.10.116.1.jpg
Figure 10.1016/j.ijcard.2016.10.116.2.jpg
Figure 10.1016/j.ijcard.2016.10.116.3.jpg

More like this: